Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
NCT05822609Phase 2Recruiting
- Sponsor
- University of Washington
- Start
- Apr 2024
- Primary completion
- Jun 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of semaglutide in diabetic kidney disease (DKD), sponsored by University of Washington. Started Apr 2024; status: recruiting.
02
Drugs
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT05822609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05822609.